# AstraZeneca’s Wainua receives FDA approval in the US

- Link: https://www.directorstalkinterviews.com/astrazenecas-wainua-receives-fda-approval-in-the-us/4121136900
- Published: 2023-12-22T07:16:49+00:00
- Author: Amilia Stone

**AstraZeneca plc** ([LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
and Ionis’ _Wainua_ (eplontersen) has been approved in the US for the treatment 
of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults,
commonly referred to as hATTR-PN or ATTRv-PN.^(1) _Wainua_ is the only approved 
medicine for the treatment of ATTRv-PN that can be self-administered via an auto-
injector.^(2-4)

The approval by the US Food and Drug Administration (FDA) was based on the positive
35-week interim analysis from the NEURO-TTRansform Phase III trial, which showed
patients treated with _Wainua_ demonstrated consistent and sustained benefit on 
the co-primary endpoints of serum transthyretin (TTR) concentration and neuropathy
impairment measured by modified Neuropathy Impairment Score +7 (mNIS+7), and key
secondary endpoint of quality of life (QoL) on the Norfolk Quality of Life Questionnaire-
Diabetic Neuropathy (Norfolk QoL-DN).^(2,5) Positive results from the NEURO-TTRansform
Phase III trial were published in _The Journal of the American Medical Association(
JAMA)_ further demonstrating the benefit of _Wainua_ across the spectrum of ATTRv-
PN at 35, 66 and 85 weeks.^(2)

> **Michael J. Polydefkis, M.D., Professor of Neurology at Johns Hopkins University
> School of Medicine and an investigator in the NEURO-TTRansform study, said**: “
> Many people living with hereditary transthyretin-mediated amyloid polyneuropathy
> are unable to fully enjoy their lives because of the relentless, progressive and
> debilitating effects of the disease. Approval of _Wainua_ represents a meaningful
> advancement in treatment, one that gives those who are living with transthyretin-
> mediated amyloid polyneuropathy help managing the disease.”

ATTRv-PN is a debilitating disease that leads to peripheral nerve damage with motor
disability within five years of diagnosis and, without treatment, is generally fatal
within a decade.^(6) _Wainua_ is a ligand-conjugated antisense oligonucleotide (
LICA) medicine designed to reduce the production of TTR protein at its source to
treat both hereditary and non-hereditary forms of transthyretin-mediated amyloidosis(
ATTR).^(3,7,8)

> **Ruud Dobber, Executive Vice-President, BioPharmaceuticals Business Unit, AstraZeneca,
> said**: “There is an urgent medical need for new therapies for people living with
> hereditary transthyretin-mediated amyloid polyneuropathy. The US approval of _Wainua_
> offers a new treatment option that provides consistent and sustained reduction
> in serum TTR concentration compared to baseline while halting disease progression
> and improving quality of life for people living with this debilitating condition.”

> **Isabelle Lousada, President and CEO, Amyloidosis Research Consortium, said**:“
> People with hereditary transthyretin-mediated amyloid polyneuropathy, and other
> forms of amyloidosis, are often misdiagnosed since symptoms can mirror other conditions.
> The path to getting an accurate diagnosis can often be a long, arduous journey
> and it is critical that a timely and accurate diagnosis is made not only for the
> individual experiencing symptoms but for their families and loved ones. It is 
> exciting to see new innovations coming through and increased efforts to raise 
> awareness in an area that has often been overlooked or neglected.”

As part of a global development and commercialisation agreement, AstraZeneca and
Ionis will commercialise _Wainua_ for the treatment of ATTRv-PN in the US and are
seeking regulatory approval in Europe and other parts of the world.^(8) This agreement
was recently expanded to include exclusive rights for AstraZeneca to commercialise
_Wainua_ in Latin America in addition to all other countries outside the US.^(9)
_Wainua_ was granted Orphan Drug Designation in the US and in the EU for the treatment
of ATTR.^(9,10) _Wainua_ will be available in the US in January 2024.

> **Brett P. Monia, Ph.D., chief executive officer at Ionis, said**: “The FDA approval
> of _Wainua_ marks an important milestone for people living with hereditary transthyretin-
> mediated amyloid polyneuropathy, who will now have an effective, well-tolerated
> treatment that can be self-administered via auto-injector to combat this devastating
> disease. It is also a pivotal moment for Ionis as _Wainua_ will be the first in
> a steady cadence of potential commercial launches for the company. We are proud
> to have discovered and, together with AstraZeneca, developed _Wainua_, and are
> grateful to the patients, caregivers and investigators who participated in our
> clinical studies, as well as for the dedication of our scientists and researchers.”

Eplontersen is currently being evaluated in the CARDIO-TTRansform Phase III trial
for treatment of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a systemic,
progressive and fatal condition that typically leads to progressive heart failure
and often death within three-to-five years from disease onset.^(11-13)  

**Notes**

**TTR Amyloidosis**

ATTR cardiomyopathy and polyneuropathy are progressive systemic diseases caused 
by aging or genetic mutations (variants), resulting in misfolded TTR protein and
accumulation as amyloid fibrils in the cardiac myocardium and peripheral nerves,
respectively.^(11,12) In patients with ATTR, both hereditary and wild type (non-
hereditary), TTR protein builds up as fibrils in tissues, such as the peripheral
nerves and heart, gastrointestinal system, eyes, kidneys, central nervous system,
thyroid and bone marrow.^(3,11) The presence of TTR fibrils interferes with the 
normal functions of these tissues.^(12) As the TTR protein fibrils accumulate, more
tissue damage occurs and the disease worsens, resulting in poor QoL and eventually
death.^(12) Worldwide, there are an estimated 300,000 – 500,000 patients with ATTR-
CM and about 40,000 patients with ATTRv-PN.^(3,12)

**NEURO-TTRansform** 
NEURO-TTRansform is a global, open-label, randomised trial
evaluating the efficacy and safety of eplontersen in patients with ATTRv-PN.^(2,5)
The trial enrolled adult patients with ATTRv-PN Stage 1 or Stage 2 compared to the
external placebo group from the TEGSEDI^(®) (inotersen) NEURO-TTR registrational
trial that Ionis completed in 2017.^(2,5)The comparison of efficacy and safety for
_Wainua_ versus external placebo was based on data up to week 66, and all patients
were followed on treatment until week 85, when they had the option to transition
into an open-label extension study, which is still ongoing.^(2,5)

**_Wainua_**_ _

_Wainua_ (eplontersen) is a ligand-conjugated antisense oligonucleotide (LICA medicine
designed to reduce the production of transthyretin, or TTR protein.^(2,7) _Wainua_
has been approved in the US for the treatment of the polyneuropathy of hereditary
transthyretin-mediated amyloidosis in adults (also referred to as ATTRv-PN).^(1)

**References**

 1.  Wainua (eplontersen) US prescribing information; 2023.
 2.  Coelho T, et al. Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.
     JAMA. 2023;330(15):1448-1458.
 3.  Ionis Pharmaceuticals [Internet]. Annual Report, 2022 [last accessed 11 December
     2023]. Available from: https://ir.ionispharma.com/static-files/db9dff5d-8683-485a-
     a517-15e264fe7532.
 4.  Benson MD, et al. Diagnosis and screening of patients with hereditary transthyretin
     amyloidosis (hATTR): Current strategies and guidelines. Ther Clin Risk Manag. 
     2020;16:4749-758.
 5.  Coelho T, et al. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study
     of Antisense Oligonucleotide AKCEA-TTR-LRx(ION-682884-CS3) in Hereditary Transthyretin-
     Mediated Amyloid Polyneuropathy. Nerol Ther. 2021 Jun;10(1):375-389.
 6.  Cortese A, et al. Diagnostic challenges in hereditary transthyretin amyloidosis
     with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy.
     J Neurol Neurosurg Psychiatry. 2017;88(5):457-458.
 7.  Coelho T, et al. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-
     Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of 
     Eplontersen. Neurol Ther. 2023;12:267-287.
 8.  Ionis Pharmaceuticals [Internet]. Eplontersen continued to show improvement in
     ATTRv-PN through 85 weeks [last accessed 11 December 2023]. Available from: https://
     ir.ionispharma.com/news-releases/news-release-details/eplontersen-continued-show-
     improvement-attrv-pn-through-85-weeks.
 9.  Ionis Pharmaceuticals [Internet]. Ionis expands eplontersen agreement with AstraZeneca
     to include exclusive rights in Latin America [last accessed 11 December 2023].
     Available from: https://ir.ionispharma.com/news-releases/news-release-details/
     ionis-expands-eplontersen-agreement-astrazeneca-include.
 10. European Commission. Commission Implementing Decision of 13.10.2023 relating to
     the designation of “Eplontersen” as an orphan medicinal product under Regulation(
     EC) No 141/2000 of the European Parliament and of the Council [last accessed 11
     December 2023]. Available from: https://ec.europa.eu/health/documents/community-
     register/2023/20231013160615/dec_160615_en.pdf.
 11. Viney N, et al. Ligand conjugated antisense oligonucleotide for the treatment 
     of transthyretin amyloidosis: preclinical and phase 1 data. ESC Heart Failure.
     2021; 8:652-661.
 12. Rintell D, et al. Patient and family experience with transthyretin amyloid cardiomyopathy(
     ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups.
     Orphanet J Rare Dis. 2021;16:70.
 13. Columbia University Irving Medical Center [Internet]. Drug Reduces Death from 
     Underdiagnosed Form of Heart Failure [last accessed 11 December 2023]. Available
     from: https://www.cuimc.columbia.edu/news/drug-reduces-deaths-underdiagnosed-form-
     heart-failure.

Share on:
